Adams Diversified Equity Fund Inc. increased its stake in Johnson Controls International plc (NYSE:JCI) by 7.6% in the third quarter, purchasing an additional 10,400 shares to own a total of 147,700 shares valued at $21,956,000. Several other institutional investors also modified their holdings, with notable increases from Amundi and Hsbc Holdings PLC. Analysts currently give Johnson Controls International a "Moderate Buy" rating with an average target price of $163.05.

Enlivex Ltd. has announced a 1-for-16 reverse share split, which will become effective on October 27, 2026, with shares trading on a split-adjusted basis on the Nasdaq Capital Market under the symbol "ENLV". This action, approved by shareholders, will reduce the number of authorized and outstanding ordinary shares and proportionately adjust the par value and exercise prices of outstanding warrants and options. The split aims to increase the per-share price without altering shareholder ownership percentages, except for minor adjustments due to fractional share rounding.

This article reports on the filing of a Form 8K by Edible Garden AG Inc. on October 22, 2026. The brief announcement provides no further details about the content of the filing but includes a stock performance indicator for EDBL.

RBC Capital has increased its price target for ONEOK Inc. from USD 90.00 to USD 96.00, while maintaining a Sector Perform rating. The adjustment follows ONEOK's strong second-quarter revenue of USD 12.05 billion and its recent acquisition of Brazos Midland. Investors are anticipating the company's third-quarter earnings release on October 27, 2026.

Colgate-Palmolive (India) Limited reported a 12.2% increase in net sales to Rs 1,692 crore for Q2 FY2026-27, with net profit rising to Rs 342 crore. The company saw double-digit domestic sales growth, driven by its premium toothpaste range and strong performance across brands and distribution channels. The board also declared an interim dividend of Rs 24 per equity share, totaling Rs 653 crore.

Global Net Lease (NYSE: GNL) is projected to announce its Q3 2026 earnings on Wednesday, November 4, 2026, after market close, with a conference call slated for November 5, 2026, at 11:00 AM ET. Analysts anticipate earnings of $0.0025 per share on revenues of $113.50 million. The company previously reported -$0.05 per share in Q2 2026, beating estimates, and has a history of surpassing EPS consensus in four of the last eight quarters.

Integrated Advisors Network LLC significantly reduced its stake in Microchip Technology Incorporated, selling 31,405 shares, which represents a 74.2% cut. Despite this, Microchip Technology exceeded analyst expectations with its recent quarterly earnings and revenue, reporting $0.76 EPS on $1.48 billion, and also declared a quarterly dividend of $0.455. The stock currently holds a "Moderate Buy" consensus rating from analysts, with an average price target of $97.71, though shares opened down 3.4% at $74.52.

Zacks Equity Research has identified five new "Strong Buy" stocks for October 23rd, based on increases in their Zacks Consensus Estimate for current or next year earnings over the last 60 days. The list includes Universal Insurance Holdings (UVE), Hasbro (HAS), Texas Instruments (TXN), United Rentals (URI), and Intuitive Surgical (ISRG), each showing positive momentum in analyst estimates.

Diversify Advisory Services LLC significantly increased its stake in Ball Corporation (NYSE:BALL) by 539.1% in the third quarter, acquiring 35,619 additional shares and bringing its total holdings to 42,226 shares valued at approximately $2.37 million. This move comes as institutional investors now own 86.51% of Ball’s outstanding shares, and analysts maintain a "Moderate Buy" consensus rating for the company with an average price target of $71. Ball recently reported strong quarterly earnings, exceeding estimates with $1.03 per share and a 19.7% year-over-year revenue increase to $4 billion, alongside a quarterly dividend payment of $0.20 per share.

Microsoft has developed an AI diagnostic tool, MAI-DxO, which significantly outperformed generalist doctors in diagnosing complex medical cases and emergency department admissions in a recent Science study. The tool, running on OpenAI’s GPT-5, operates by simulating a panel of clinical experts, gathering information, and revising diagnoses step-by-step. While showing promising accuracy and cost-effectiveness, the system is not yet in clinical use and has limitations, such as not having access to physical examinations or medical imaging in the study.